Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC lessened its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 91.3% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,244 shares of the biopharmaceutical company’s stock after selling 44,534 shares during the period. SG Americas Securities LLC’s holdings in Intra-Cellular Therapies were worth $311,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Headlands Technologies LLC bought a new stake in shares of Intra-Cellular Therapies in the 1st quarter worth approximately $32,000. Fidelis Capital Partners LLC acquired a new stake in shares of Intra-Cellular Therapies during the first quarter valued at approximately $53,000. Summit Securities Group LLC purchased a new stake in shares of Intra-Cellular Therapies in the 2nd quarter valued at approximately $56,000. CWM LLC boosted its stake in Intra-Cellular Therapies by 83.9% in the 2nd quarter. CWM LLC now owns 1,372 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 626 shares during the period. Finally, EntryPoint Capital LLC lifted its holdings in shares of Intra-Cellular Therapies by 138.7% in the first quarter. EntryPoint Capital LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $150,000 after purchasing an additional 1,259 shares in the last quarter. 92.33% of the stock is currently owned by institutional investors.

Insider Activity at Intra-Cellular Therapies

In related news, CEO Sharon Mates sold 53,013 shares of the company’s stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $75.65, for a total transaction of $4,010,433.45. Following the sale, the chief executive officer now owns 1,070,329 shares in the company, valued at approximately $80,970,388.85. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, EVP Mark Neumann sold 18,714 shares of Intra-Cellular Therapies stock in a transaction on Friday, August 16th. The stock was sold at an average price of $75.08, for a total value of $1,405,047.12. Following the transaction, the executive vice president now owns 29,700 shares in the company, valued at approximately $2,229,876. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Sharon Mates sold 53,013 shares of Intra-Cellular Therapies stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $75.65, for a total value of $4,010,433.45. Following the sale, the chief executive officer now directly owns 1,070,329 shares in the company, valued at $80,970,388.85. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 175,316 shares of company stock worth $13,037,345. 3.40% of the stock is owned by company insiders.

Analysts Set New Price Targets

ITCI has been the topic of several research reports. Needham & Company LLC reiterated a “buy” rating and issued a $100.00 price objective on shares of Intra-Cellular Therapies in a research note on Wednesday, August 7th. Morgan Stanley increased their price objective on Intra-Cellular Therapies from $92.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Cantor Fitzgerald restated an “overweight” rating and issued a $130.00 price objective on shares of Intra-Cellular Therapies in a report on Monday, September 16th. Piper Sandler upgraded shares of Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $68.00 to $92.00 in a research note on Friday, September 6th. Finally, JPMorgan Chase & Co. raised their target price on Intra-Cellular Therapies from $79.00 to $81.00 and gave the company an “overweight” rating in a report on Wednesday, August 21st. Two equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $96.62.

Intra-Cellular Therapies Price Performance

NASDAQ ITCI opened at $78.34 on Friday. The stock’s 50 day simple moving average is $74.43 and its 200 day simple moving average is $72.49. Intra-Cellular Therapies, Inc. has a one year low of $45.50 and a one year high of $84.89. The firm has a market cap of $8.27 billion, a PE ratio of -67.53 and a beta of 1.00.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.03. The company had revenue of $161.40 million during the quarter, compared to analysts’ expectations of $157.74 million. Intra-Cellular Therapies had a negative return on equity of 11.48% and a negative net margin of 14.93%. The business’s revenue for the quarter was up 45.7% on a year-over-year basis. During the same period last year, the firm earned ($0.45) EPS. As a group, equities analysts expect that Intra-Cellular Therapies, Inc. will post -0.59 earnings per share for the current year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.